Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 24Gynecologic 7Breast 3Thoracic 2Other solid neoplasm 2Genitourinary 2Gastrointestinal 2CNS 2Classical hematology 1

Conditions

Breast Neoplasms 3Neoplasms 2Skin Diseases 1Sarcoma 1Ovarian Neoplasms 1Neoplasms by Site 1Breast Diseases 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 215Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Trabectedin × Breast × Clear all
NCT00786838 2014-04-11

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
76 enrolled 17 charts
BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00580112 2014-02-25

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
127 enrolled
Breast

Breast Neoplasms

NCT00050427 2011-04-28

A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
53 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡